ERBB2 and cancer: The correlation between overexpression of EGFR1 and downregulation of Her2 with a poor clinical outcome highlights the need for a targeted therapy for increasing the efficacy and safety profiles of the drugs by aiming for the cancer cells without affecting the healthy cells (Figure 1).